Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188550 | 0.91 | MAPT (0.50) | MAPTHTTALDH1A1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL25373638 | 0.90 | MAPT (0.49) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL831000 | 0.88 | HDAC1 (0.50) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL13933074 | 0.88 | HDAC1 (0.50) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL17262864 | 0.88 | HDAC1 (0.50) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL11233455 | 0.85 | MAPT (0.66) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL10738896 | 0.84 | L3MBTL1 (0.68) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL7697086 | 0.84 | MAPT (0.53) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL1932026 | 0.84 | MAPT (0.53) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL1668551 | 0.83 | LTA4H (0.52) | MAPTHTTALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | LIU, MIAO (CN) | 2023-08-10 | — | — | US | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| US-9855268-B2 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1928827-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | MAPT 6/4885HTT 12/4885ALDH1A1 4389/4885 |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | EIF2AK4, CDK2, CDK1 | MAPT 4608/4885HTT 2833/4885ALDH1A1 4833/4885 |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | MAPT 30/4885HTT 12/4885ALDH1A1 2759/4885 |
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | VIP, GHITM, MYCBP | MAPT 4121/4885HTT 1434/4885ALDH1A1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.